Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]
- Market Cap ₹ 10,933 Cr.
- Current Price ₹ 387
- High / Low ₹ 513 / 348
- Stock P/E 11.4
- Book Value ₹ 339
- Dividend Yield 0.65 %
- ROCE 16.0 %
- ROE 13.6 %
- Face Value ₹ 1.00
Pros
- Stock is trading at 1.14 times its book value
Cons
- The company has delivered a poor sales growth of 6.27% over past five years.
- Company has a low return on equity of 13.6% over last 3 years.
- Company might be capitalizing the interest cost
- Dividend payout has been low at 7.95% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2,949 | 4,021 | 5,012 | 6,005 | 6,563 | 7,562 | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,305 | 12,345 | |
2,357 | 3,306 | 3,997 | 4,914 | 5,348 | 6,125 | 7,043 | 7,457 | 8,280 | 8,942 | 8,860 | 9,978 | 10,135 | |
Operating Profit | 592 | 714 | 1,015 | 1,091 | 1,214 | 1,437 | 2,037 | 1,617 | 1,586 | 1,699 | 2,084 | 2,327 | 2,210 |
OPM % | 20% | 18% | 20% | 18% | 18% | 19% | 22% | 18% | 16% | 16% | 19% | 19% | 18% |
145 | 18 | 11 | 11 | -180 | 20 | -44 | 89 | 375 | 191 | 95 | -101 | 141 | |
Interest | 160 | 147 | 160 | 189 | 190 | 179 | 237 | 286 | 335 | 377 | 353 | 298 | 297 |
Depreciation | 95 | 98 | 127 | 217 | 300 | 234 | 264 | 302 | 326 | 417 | 444 | 487 | 553 |
Profit before tax | 482 | 488 | 739 | 697 | 544 | 1,044 | 1,491 | 1,119 | 1,301 | 1,096 | 1,382 | 1,441 | 1,501 |
Tax % | 5% | 5% | 15% | 22% | 61% | 29% | 26% | 28% | 29% | 29% | 30% | 31% | |
Net Profit | 458 | 464 | 628 | 546 | 209 | 743 | 1,109 | 804 | 925 | 776 | 970 | 994 | 902 |
EPS in Rs | 16.77 | 17.02 | 22.89 | 19.99 | 7.72 | 26.33 | 39.29 | 28.49 | 32.78 | 27.50 | 34.38 | 33.37 | 29.42 |
Dividend Payout % | 2% | 3% | 0% | 0% | 26% | 8% | 5% | 7% | 6% | 9% | 7% | 7% |
Compounded Sales Growth | |
---|---|
10 Years: | 12% |
5 Years: | 6% |
3 Years: | 8% |
TTM: | 5% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | -1% |
3 Years: | 10% |
TTM: | -8% |
Stock Price CAGR | |
---|---|
10 Years: | -3% |
5 Years: | -8% |
3 Years: | 8% |
1 Year: | -24% |
Return on Equity | |
---|---|
10 Years: | 17% |
5 Years: | 14% |
3 Years: | 14% |
Last Year: | 14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
27 | 27 | 27 | 27 | 27 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | |
Reserves | 2,010 | 2,375 | 2,736 | 2,956 | 1,756 | 3,601 | 4,464 | 5,135 | 5,577 | 6,042 | 7,036 | 9,058 | 9,545 |
2,108 | 2,244 | 2,765 | 3,267 | 3,800 | 3,988 | 4,724 | 4,639 | 4,449 | 4,869 | 4,986 | 3,962 | 4,240 | |
804 | 1,087 | 1,466 | 2,176 | 2,726 | 2,575 | 2,548 | 2,793 | 3,235 | 3,729 | 3,524 | 4,003 | 4,218 | |
Total Liabilities | 4,950 | 5,733 | 6,994 | 8,427 | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 18,031 |
2,034 | 2,223 | 2,822 | 3,091 | 2,015 | 2,594 | 2,755 | 3,030 | 3,670 | 5,029 | 5,129 | 5,887 | 6,146 | |
CWIP | 178 | 263 | 6 | 5 | 477 | 543 | 708 | 1,122 | 1,399 | 1,222 | 1,382 | 1,010 | 1,176 |
Investments | 0 | 0 | 0 | 0 | 17 | 17 | 16 | 15 | 30 | 25 | 25 | 50 | 45 |
2,738 | 3,248 | 4,166 | 5,331 | 5,799 | 7,039 | 8,285 | 8,429 | 8,190 | 8,393 | 9,040 | 10,105 | 10,665 | |
Total Assets | 4,950 | 5,733 | 6,994 | 8,427 | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 18,031 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
931 | 804 | 648 | 854 | 482 | 345 | 657 | 1,648 | 1,324 | 1,392 | 1,131 | 1,109 | |
-404 | -318 | -558 | -566 | -712 | -950 | -1,001 | -1,003 | -883 | -774 | -662 | -316 | |
-436 | -361 | 195 | -98 | 199 | 699 | 543 | -468 | -739 | -445 | -442 | -520 | |
Net Cash Flow | 91 | 125 | 285 | 190 | -31 | 93 | 199 | 177 | -297 | 174 | 28 | 272 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 140 | 113 | 119 | 131 | 140 | 120 | 97 | 94 | 81 | 83 | 86 | 92 |
Inventory Days | 310 | 223 | 194 | 191 | 247 | 249 | 299 | 244 | 244 | 211 | 230 | 212 |
Days Payable | 252 | 220 | 239 | 279 | 379 | 308 | 243 | 225 | 241 | 210 | 226 | 194 |
Cash Conversion Cycle | 197 | 116 | 75 | 43 | 8 | 61 | 152 | 113 | 85 | 84 | 90 | 110 |
Working Capital Days | 202 | 150 | 94 | 83 | 66 | 89 | 133 | 111 | 76 | 69 | 96 | 100 |
ROCE % | 15% | 14% | 18% | 15% | 16% | 19% | 21% | 15% | 15% | 14% | 15% | 16% |
Documents
Announcements
- Update On The Company''s Baddi (India) Facility 27 Jan
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
23 Jan - Glenmark launches AKYNZEO® I.V. in India - First Fixed I.V. Antiemetic Combination for the Prevention of Chemotherapy-induced Nausea and Vomiting
- Glenmark Pharmaceuticals Ltd. To Divest Select Brands And Sub-Brands ('Tail Brands') From Its Dermatology Segment, For India And Nepal Territories, To Eris Oaknet Healthcare Private Limited. 17 Jan
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
17 Jan - Details of Earnings Call slated for Monday, February 13, 2023 at 9:30 a.m. - 10:30 a.m. (IST), for your information and record. Please note that …
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
17 Jan - Heart failure treatment becomes more affordable with Glenmark launching the Sacubitril + Valsartan tablets in India
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
Nov 2022TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022TranscriptPPT
-
Feb 2022TranscriptPPT REC
-
Nov 2021TranscriptPPT REC
-
Aug 2021TranscriptPPT REC
-
May 2021TranscriptPPT REC
-
Feb 2021TranscriptPPTREC
-
Nov 2020TranscriptPPTREC
-
Aug 2020TranscriptPPTREC
-
Jun 2020TranscriptPPTREC
-
Feb 2020TranscriptPPTREC
-
Nov 2019TranscriptPPTREC
-
Aug 2019TranscriptPPTREC
-
May 2019TranscriptPPTREC
-
Feb 2019TranscriptPPT REC
-
Nov 2018TranscriptPPTREC
-
Aug 2018TranscriptPPTREC
-
May 2018TranscriptPPTREC
-
Feb 2018TranscriptPPTREC
-
Nov 2017TranscriptPPTREC
-
Aug 2017TranscriptPPTREC
-
May 2017TranscriptPPTREC
-
Feb 2017TranscriptPPT REC
-
Dec 2016TranscriptPPT
-
Jul 2016TranscriptPPT
-
May 2016TranscriptPPTREC
-
Jan 2016TranscriptPPT
Product Offerings
The company offers a wide range of pharma products/ drugs in the form of oral solids, liquids, topical products, respiratory MDI/DPI and complex injectables & biologics. It is primarily focused on therapy areas of dermatology, respiratory and oncology.[1]